BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT; and the VAST-D Investigators. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017;318:132-45. [PMID: 28697253 DOI: 10.1001/jama.2017.8036] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Seetasith A, Greene M, Hartry A, Burudpakdee C. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder. Journal of Medical Economics 2018;21:888-901. [DOI: 10.1080/13696998.2018.1484373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Chen P. Optimized Treatment Strategy for Depressive Disorder. In: Fang Y, editor. Depressive Disorders: Mechanisms, Measurement and Management. Singapore: Springer; 2019. pp. 201-17. [DOI: 10.1007/978-981-32-9271-0_11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Seeman MV, González-Rodríguez A. Use of psychotropic medication in women with psychotic disorders at menopause and beyond. Curr Opin Psychiatry 2018;31:183-92. [PMID: 29528895 DOI: 10.1097/YCO.0000000000000410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Jones BDM, Husain MI, Mulsant BH. The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review. Expert Opin Pharmacother 2021;22:1005-14. [PMID: 33612048 DOI: 10.1080/14656566.2021.1878144] [Reference Citation Analysis]
5 Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020;15:e0239206. [PMID: 32997687 DOI: 10.1371/journal.pone.0239206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Nemeroff CB. The Search for Treatments for Veterans With Major Depression: Of Paramount Importance, yet Still Elusive. JAMA Psychiatry 2018;75:877-8. [PMID: 29955814 DOI: 10.1001/jamapsychiatry.2018.1591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Day E, Shah R, Taylor RW, Marwood L, Nortey K, Harvey J, McAllister-Williams RH, Geddes JR, Barrera A, Young AH, Cleare AJ, Strawbridge R. A retrospective examination of care pathways in individuals with treatment-resistant depression. BJPsych Open 2021;7:e101. [PMID: 33988121 DOI: 10.1192/bjo.2021.59] [Reference Citation Analysis]
8 Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 2019;12:CD010557. [PMID: 31846068 DOI: 10.1002/14651858.CD010557.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tong P, Bu P, Yang Y, Dong L, Sun T, Shi Y. Group cognitive behavioural therapy can reduce stigma and improve treatment compliance in major depressive disorder patients. Early Interv Psychiatry 2020;14:172-8. [PMID: 31264787 DOI: 10.1111/eip.12841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Aaronson ST, Carpenter LL, Hutton TM, Kraus S, Mina M, Pages K, Shi L, West WS, Sackeim HA. Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry. Brain Stimulation 2022. [DOI: 10.1016/j.brs.2022.01.006] [Reference Citation Analysis]
11 Kutzer T, Dick M, Scudamore T, Wiener M, Schwartz T. Antidepressant efficacy and side effect burden: an updated guide for clinicians. Drugs Context 2020;9:2020-2-2. [PMID: 32523610 DOI: 10.7573/dic.2020-2-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Zisook S, Mohamad S, Johnson G, Tal I, Villarreal G, Wilcox JA, Shear KM. Clinical implications of co-occurring prolonged grief disorder in patients with treatment-resistant major depressive disorder. World Psychiatry 2021;20:303-4. [PMID: 34002524 DOI: 10.1002/wps.20877] [Reference Citation Analysis]
13 Gautam M, Patel S, Zarkowski P. Practice patterns of bupropion co-prescription with antipsychotic medications. Journal of Addictive Diseases. [DOI: 10.1080/10550887.2022.2028531] [Reference Citation Analysis]
14 Rhee TG, Rosenheck RA. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. J Affect Disord 2019;252:450-7. [PMID: 31004825 DOI: 10.1016/j.jad.2019.04.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
15 Yermilov I, Greene M, Chang E, Hartry A, Yan T, Broder MS. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data. Adv Ther 2018;35:2138-51. [PMID: 30456519 DOI: 10.1007/s12325-018-0838-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA, Kieling C. The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2020;33:139-45. [PMID: 32046933 DOI: 10.1016/j.euroneuro.2020.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015. J Clin Psychiatry 2018;79:17m11970. [PMID: 29469245 DOI: 10.4088/JCP.17m11970] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
18 Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel) 2020;13:E116. [PMID: 32512768 DOI: 10.3390/ph13060116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
19 Xing S, Calip GS, Leow AD, Kim S, Schumock GT, Touchette DR, Lee TA. The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. J Diabetes Complications 2018;32:492-500. [PMID: 29544744 DOI: 10.1016/j.jdiacomp.2017.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment. Clin Ther 2019;41:221-32. [PMID: 30616973 DOI: 10.1016/j.clinthera.2018.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Jha MK. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy from a Phase 2B Study of Seltorexant. Int J Neuropsychopharmacol 2021:pyab078. [PMID: 34791262 DOI: 10.1093/ijnp/pyab078] [Reference Citation Analysis]
22 Kim JM, Stewart R, Kang HJ, Kim JW, Lee HJ, Jhon M, Lee JY, Kim SW, Shin IS. Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders. J Affect Disord 2020;274:315-25. [PMID: 32469822 DOI: 10.1016/j.jad.2020.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Yesavage JA, Fairchild JK, Mi Z, Biswas K, Davis-Karim A, Phibbs CS, Forman SD, Thase M, Williams LM, Etkin A, O'Hara R, Georgette G, Beale T, Huang GD, Noda A, George MS; VA Cooperative Studies Program Study Team. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. JAMA Psychiatry 2018;75:884-93. [PMID: 29955803 DOI: 10.1001/jamapsychiatry.2018.1483] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
24 Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S. The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2021:pyab066. [PMID: 34637516 DOI: 10.1093/ijnp/pyab066] [Reference Citation Analysis]
25 Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. [PMID: 35171215 DOI: 10.1001/jamapsychiatry.2021.4313] [Reference Citation Analysis]
26 Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, Colmegna F, Clerici M, Buoli M, Dakanalis A. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. Int J Mol Sci 2021;22:13070. [PMID: 34884874 DOI: 10.3390/ijms222313070] [Reference Citation Analysis]
27 Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, Zhang L, Feng Y, Ng CH. Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatr Dis Treat 2020;16:2943-59. [PMID: 33299316 DOI: 10.2147/NDT.S264813] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Westermeyer J. Call for “High-Dose” Olanzapine Research in Treatment-Resistant Psychosis. J Nerv Ment Dis 2019;207:45-7. [DOI: 10.1097/nmd.0000000000000909] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Fugger G, Bartova L, Dold M, Fabbri C, Fanelli G, Zanardi R, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2022;114:110480. [PMID: 34826558 DOI: 10.1016/j.pnpbp.2021.110480] [Reference Citation Analysis]
30 Dubovsky SL. What Is New about New Antidepressants? Psychother Psychosom 2018;87:129-39. [PMID: 29788008 DOI: 10.1159/000488945] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
31 Giakoumatos CI, Osser D. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression. Harv Rev Psychiatry 2019;27:33-52. [DOI: 10.1097/hrp.0000000000000197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
32 Mulder R, Hamilton A, Irwin L, Boyce P, Morris G, Porter RJ, Malhi GS. Treating depression with adjunctive antipsychotics. Bipolar Disord 2018;20:17-24. [DOI: 10.1111/bdi.12701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
33 Zisook S, Johnson GR, Hicks P, Chen P, Beresford T, Michalets JP, Rao S, Thase ME, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report. Depress Anxiety 2021;38:185-95. [PMID: 33225492 DOI: 10.1002/da.23114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Reutfors J, Brenner P, Brody B, Wray H, Andersen M, Brandt L. A Post-Authorization Safety Study of Quetiapine as Antidepressant Treatment in Sweden: Nested Case-Control Analyses of Select Outcomes. Drug Saf 2020;43:135-45. [PMID: 31848933 DOI: 10.1007/s40264-019-00889-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:1827-45. [PMID: 30975301 DOI: 10.1016/j.jacc.2019.01.041] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 23.0] [Reference Citation Analysis]
36 Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs 2020;34:1133-47. [PMID: 33064291 DOI: 10.1007/s40263-020-00763-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Zarate CA Jr. What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments? Am J Geriatr Psychiatry 2017;25:1210-2. [PMID: 28939286 DOI: 10.1016/j.jagp.2017.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Li M, Kouzmina E, McCusker M, Rodin D, Boutros PC, Paige CJ, Rodin G. Cytokines and depression in cancer patients and caregivers. Neuropsychiatr Dis Treat 2017;13:2903-11. [PMID: 29238195 DOI: 10.2147/NDT.S144774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
39 Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022. [DOI: 10.1016/j.genhosppsych.2022.03.008] [Reference Citation Analysis]
40 Burnaska DR, Huang GD, O'Leary TJ. Clinical trials proposed for the VA Cooperative Studies Program: Success rates and factors impacting approval. Contemp Clin Trials Commun 2021;23:100811. [PMID: 34307958 DOI: 10.1016/j.conctc.2021.100811] [Reference Citation Analysis]
41 Perna G, Daccò S, Alciati A, Cuniberti F, De Berardis D, Caldirola D. Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2021;107:110208. [PMID: 33338557 DOI: 10.1016/j.pnpbp.2020.110208] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Pyke RE, Clayton AH. Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions. Sexual Medicine Reviews 2019;7:551-8. [DOI: 10.1016/j.sxmr.2019.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Kimmel MC, Cox E, Schiller C, Gettes E, Meltzer-brody S. Pharmacologic Treatment of Perinatal Depression. Obstetrics and Gynecology Clinics of North America 2018;45:419-40. [DOI: 10.1016/j.ogc.2018.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
44 Baune BT, Falkai P. Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent. Aust N Z J Psychiatry 2021;55:1033-8. [PMID: 33111538 DOI: 10.1177/0004867420968912] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Chae WR, Schienkiewitz A, Du Y, Hapke U, Otte C, Michalski N. Comorbid depression and obesity among adults in Germany: Effects of age, sex, and socioeconomic status. J Affect Disord 2021;299:383-92. [PMID: 34910960 DOI: 10.1016/j.jad.2021.12.025] [Reference Citation Analysis]
46 Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K, Ikeda Y, Shinagawa Y, Kondo M, Okamoto Y, Fujita H, Suga M, Yasumoto S, Tsujino N, Inoue T, Fujise N, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M, Miki K, Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Shinohara K, Yonemoto N, Tanaka S, Zhou Q, Guyatt GH; SUN☺D Investigators. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med 2018;16:103. [PMID: 29991347 DOI: 10.1186/s12916-018-1096-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
47 Bhatt DL, Hull MA, Song M, Van Hulle C, Carlsson C, Chapman MJ, Toth PP. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. Eur Heart J Suppl 2020;22:J54-64. [PMID: 33061868 DOI: 10.1093/eurheartj/suaa119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Bazinet RP, Metherel AH, Chen CT, Shaikh SR, Nadjar A, Joffre C, Layé S. Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression. Brain Behav Immun 2020;85:21-8. [PMID: 31278982 DOI: 10.1016/j.bbi.2019.07.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
49 Zhang H, Wu Z, Cao L, Su Y, Wang F, Hong W, Cai Y, Peng D, Fang Y. Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. J Affect Disord 2022;297:68-75. [PMID: 34670132 DOI: 10.1016/j.jad.2021.10.011] [Reference Citation Analysis]
50 Yavi M, Henter ID, Park LT, Zarate C. Key considerations in the pharmacological management of treatment-resistant depression. Expert Opin Pharmacother 2021;:1-11. [PMID: 34252320 DOI: 10.1080/14656566.2021.1951225] [Reference Citation Analysis]
51 Ang YS, Kaiser R, Deckersbach T, Almeida J, Phillips ML, Chase HW, Webb CA, Parsey R, Fava M, McGrath P, Weissman M, Adams P, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Cooper CM, Chin Fatt CR, Trivedi MH, Pizzagalli DA. Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biol Psychiatry 2020;88:657-67. [PMID: 32507389 DOI: 10.1016/j.biopsych.2020.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
52 Cristancho P, Lenard E, Lenze EJ, Miller JP, Brown PJ, Roose SP, Montes-Garcia C, Blumberger DM, Mulsant BH, Lavretsky H, Rollman BL, Reynolds CF 3rd, Karp JF. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. Am J Geriatr Psychiatry 2019;27:1138-52. [PMID: 31147244 DOI: 10.1016/j.jagp.2019.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
53 Kalaria S, Spence O, Hong K, dosReis S, Gopalakrishnan M. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study. Clin Pharmacol Ther 2021;110:443-51. [PMID: 33811324 DOI: 10.1002/cpt.2249] [Reference Citation Analysis]
54 Köhler-Forsberg O, Larsen ER, Buttenschøn HN, Rietschel M, Hauser J, Souery D, Maier W, Farmer A, McGuffin P, Aitchison KJ, Uher R, Mors O. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. Br J Psychiatry 2019;215:494-501. [PMID: 30698114 DOI: 10.1192/bjp.2018.302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
55 Kern DM, Cepeda MS, Castilla-Puentes RC, Savitz A, Etropolski M. Characteristics of patients with major depressive disorder switching SSRI/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting. Curr Med Res Opin 2021;37:1377-84. [PMID: 33818238 DOI: 10.1080/03007995.2021.1911975] [Reference Citation Analysis]